Clinical trials: Movement Abnormalities
Huntington's Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
- Trial name
- NCT03342053
- Testing
- RO7234292 (RG6042)
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease, Cognitive Impairment, Mild
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease.
- Conditions
- Parkinson Disease, Cognitive Impairment, Mild, Speech
- Trial name
- SLAM-PD (NCT04273672)
- Testing
- Cognitive Battery, Voice, Speech and Language Analysis, Questionnaires and Clinical Assessments
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Parkinson Disease
Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease
The present study aims to investigate the effect of transcranial direct current stimulation (tDCS) associated with physiotherapy in parkinson´s rehabilitation.
- Trial name
- NCT01877148
- Testing
- tDCS, Physiotherapy
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Universidade Federal de Pernambuco
Parkinson's Disease, Cognitive Impairment
Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
The purpose of this study is to determine the safety and effectiveness of a drug called atomoxetine for the treatment of cognitive impairment for Parkinson 's disease.
- Trial name
- ATM-Cog (NCT01738191)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Parkinson's Disease
Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS
Our recent study (Xie et al, Neurology 2015; 84: 415-420) found that bilateral STN DBS of 60Hz, compared to the traditional 130Hz, decreased the aspiration frequency and swallowing difficulty, freezing of gait (FOG), and other…
- Trial name
- NCT02549859
- Testing
- Deep Brain Stimulation (DBS) at 60 Hz, Deep Brain Stimulation (DBS) at 130 Hz
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Parkinson Disease
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose levels of THN102 to placebo in patients suffering from Parkinson's disease associated with excessive daytime sleepiness.
- Trial name
- NCT03624920
- Testing
- THN102 Dosage A, THN102 Dosage B, THN102 Dosage C
- Where
- 34 sites in United States, Czechia and 3 more
- Volunteers
- 77 people
- Sponsor
- Theranexus
Dementia With Lewy Bodies (DLB)
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00598650
- Testing
- E2020
- Volunteers
- 160 people
- Sponsor
- Eisai Co., Ltd.
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Parkinson's Disease
Cognitive Dysfunction in Parkinson's Disease
This study plans to learn more about the brain function related to thinking problems in individuals with Parkinson's disease.
- Trial name
- NCT02346708
- Testing
- Real TMS
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Colorado, Denver
Multiple System Atrophy
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
- Trial name
- NCT05526391
- Testing
- TAK-341
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 158 people
- Sponsor
- Takeda
Wilson Disease
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
This was a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of celecoxib, a sensitive cytochrome P450 2C9 (CYP2C9) substrate, in healthy male and female…
- Trial name
- NCT04526197
- Testing
- ALXN1840, Celecoxib
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson Disease
Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
- Trial name
- NCT02212678
- Testing
- N-acetylcysteine capsule
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Parkinson's Disease
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease
The purpose of this research study is to attempt to treat apathy in Parkinson's disease (PD) using high-frequency repetitive transcranial magnetic stimulation (rTMS) of the brain and to investigate the patterns of brain…
- Trial name
- ReStore (NCT00955032)
- Testing
- High-Frequency Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Parkinson Disease, Cognitive Impairment
Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease.
- Trial name
- NCT03204526
- Testing
- deep brain stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Parkinson Disease
Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
To assess the pharmacokinetics of BIA 9-1067 in healthy Japanese subjects
- Trial name
- NCT01520987
- Testing
- BIA 9-1067
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the…
- Trial name
- NCT03521635
- Testing
- Pramipexole SR, Pramipexole IR
- Where
- 12 sites in China
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Huntington's Disease
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in…
- Trial name
- PRECISION-HD1 (NCT03225833)
- Testing
- WVE-120101
- Where
- 21 sites in Australia, Canada and 5 more
- Volunteers
- 61 people
- Sponsor
- Wave Life Sciences USA, Inc.
Irritable Mood, Huntington's Disease
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease.
- Trial name
- NCT02507284
- Testing
- SRX246
- Where
- 22 sites in United States
- Volunteers
- 106 people
- Sponsor
- Azevan Pharmaceuticals
Parkinson Disease, Movement Disorders
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.
- Trial name
- NCT05636852
- Testing
- Altropane (123I) Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- GE Healthcare